Investment
Features
FeesSafety
Academy
More
Pluang+

Flyte Aviation launches Partner Portal to streamline B2B private jet bookings with exclusive pricing.

Market News
20 Oct 2026
GlobeNewsWire
View Source
Bullish
Flyte Aviation launches Partner Portal to streamline B2B private jet bookings with exclusive pricing.

Flyte Aviation has introduced the Flyte Partner Portal, a new digital platform that offers strategic partners dedicated accounts, easier booking access, and exclusive preferred pricing for private aviation services. This launch marks a key step in Flyte's strategy to modernize private aviation by replacing outdated manual booking methods with a scalable, tech-driven B2B distribution channel. The portal leverages Flyte's partnerships across hospitality, sports, entertainment, and luxury lifestyle sectors, aiming to boost customer acquisition, flight volume, and aircraft utilization. Flyte's recent growth includes over 20,000 platform users and record Q3 2026 revenue of $2.1 million, highlighting strong momentum as it reshapes private aviation accessibility and efficiency.

Flyte Aviation's new B2B distribution channel launch comes as 103 of 134 Consumer Cyclical-sector US stocks on Pluang rose today. For readers following this sector, here is Pluang's market snapshot as of Oct 21, 2026 02:31 WIB: ATER (Aterian Inc) gained 8.65% to USD 0.60 with a typical hold time of 27 days and 74% sell order activity; XPEV (Xpeng Inc - ADR) rose 7.38% to USD 9.89, held typically for 81 days with 90% sell orders; GM (General Motors Company) fell 6.98% to USD 76.97, held for 83 days with 95% sell orders.

More News

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's Q3 2026 earnings preview highlights credit ratings and AI-driven analytics growth.

Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...

Company Fundamentals
Neutral
39 minutes ago
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.

Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...

Analyst Insights
Bullish
1 hour ago
Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express Q3 revenue falls 8.7%, misses estimates but returns to profit

Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...

Company Fundamentals
Bearish
1 hour ago
CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

CMMB opens new Distribution Center at Brethren Service Center to boost global medicine access.

Catholic Medical Mission Board (CMMB) held a ribbon-cutting ceremony for its new Distribution Center at the Brethren Service Center in New Windsor, Maryland. This move enhances CMMB's Access to Medicines Program by expanding operational capacity and ...

Others
Neutral
1 hour ago
Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Myriad Genetics upgraded to Neutral as it sells prenatal unit to Labcorp for $210M.

Piper Sandler upgraded Myriad Genetics from Underweight to Neutral and set a $5.00 price target after the company agreed to sell its prenatal health testing business to Labcorp for $210 million in cash. This sale includes several prenatal tests and i...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App